Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 1/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.62 |
| ▸ | MARS1 | P56192 | 6/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821771 | 0.94 | RPA1 (0.61) | RPA1CHRNA7GABRA2GABRB2MARS1 | |
| SCHEMBL29419099 | 0.93 | MARS1 (0.68) | RPA1CHRNA7GABRA2GABRB2MARS1 | |
| SCHEMBL342100 | 0.93 | MARS1 (0.68) | RPA1CHRNA7GABRA2GABRB2MARS1 | |
| SCHEMBL4693715 | 0.90 | CHRNA7 (0.61) | RPA1CHRNA7GABRA2GABRB2MARS1 | |
| SCHEMBL2982610 | 0.87 | RPA1 (0.73) | RPA1GABRA2GABRB2MARS1MEN1 | |
| SCHEMBL29419139 | 0.87 | GABRA2 (0.59) | CHRNA7GABRA2GABRB2FAAHMEN1 | |
| SCHEMBL340947 | 0.87 | GABRA2 (0.59) | CHRNA7GABRA2GABRB2FAAHMEN1 | |
| SCHEMBL3816384 | 0.86 | MARS1 (0.57) | RPA1CHRNA7GABRA2GABRB2MARS1 | |
| SCHEMBL3818522 | 0.86 | CHRNA7 (0.54) | RPA1CHRNA7GABRA2GABRB2MARS1 | |
| SCHEMBL5797399 | 0.84 | GABRA2 (0.57) | CHRNA7GABRA2GABRB2FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015162452-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CB1 RECEPTOR ANTAGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-10-29 | — | — | WO | disclosed |
| US-8354442-B2 | Imidazol-4-one and imidazole-4-thione compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-01-15 | — | — | US | disclosed |
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| WO-2010062686-A2 | IMIDAZOL-4-ONE AND IMIDAZOLE-4-THIONE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-06 | — | — | US | disclosed |
| EP-2097410-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Green Cross Corporation (KR) | 2009-09-09 | — | — | EP | disclosed |
| EP-2084135-A2 | PYRAZOLE COMPOUNDS | National Health Research Institutes (TW) | 2009-08-05 | — | — | EP | disclosed |
| US-20090042864-A2 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-02-12 | — | — | US | disclosed |
| WO-2008060771-A2 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-22 | — | — | WO | disclosed |
| US-20080090809-A1 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-17 | — | — | US | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039023-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039023-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | WO | disclosed |
| US-20060025448-A1 | Hair growth stimulators | CADILA HEALTHCARE LIMITED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042864-A2 | PYRAZOLE COMPOUNDS | CNR2, CNR1, GPR18 | RPA1 4829/4885CHRNA7 215/4885GABRA2 45/4885 |
| US-20060025448-A1 | Hair growth stimulators | NGF, CNR2, CNR1 | RPA1 4614/4885CHRNA7 1573/4885GABRA2 881/4885 |
| US-20080090809-A1 | PYRAZOLE COMPOUNDS | CNR2, CNR1, GPR18 | RPA1 4829/4885CHRNA7 215/4885GABRA2 45/4885 |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | CNR1, CNR2, HRH4 | RPA1 4598/4885CHRNA7 136/4885GABRA2 353/4885 |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | RPA1 4739/4885CHRNA7 687/4885GABRA2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.